Obrietan, Karl and Anthony N. van den Pol. GABA B receptormediated regulation of glutamate-activated calcium transients in hypothalamic and cortical neuron development. J. Neurophysiol. 81: 94 -102, 1999. In the mature nervous system excitatory neurotransmission mediated by glutamate is balanced by the inhibitory actions of GABA. However, during early development, GABA acting at the ligand-gated GABA A Cl Ϫ channel also exerts excitatory actions. This raises a question as to whether GABA can exert inhibitory activity during early development, possibly by a mechanism that involves activation of the G protein-coupled GABA B receptor. To address this question we used Ca 2ϩ digital imaging to assess the modulatory role of GABA B receptor signaling in relation to the excitatory effects of glutamate during hypothalamic and cortical neuron development. Ca 2ϩ transients mediated by synaptic glutamate release in neurons cultured from embryonic rat were dramatically depressed by the administration of the GABA B receptor agonist baclofen in a dosedependent manner. The inhibitory effects of GABA B receptor activation persisted for the duration of baclofen administration (Ͼ10 min). Preincubation with the Gi protein inhibitor pertussis toxin resulted in a substantial decrease in the inhibitory actions of baclofen, confirming that a Gi-dependent mechanism mediated the effects of the GABA B receptor. Co-administration of the GABA B receptor antagonist 2-hydroxy-saclofen eliminated the inhibitory action of baclofen. Alone, GABA B antagonist application elicited a marked potentiation of Ca 2ϩ transients mediated by glutamatergic neurotransmission, suggesting that tonic synaptic GABA release exerts an inhibitory tone on glutamate receptor-mediated Ca 2ϩ transients via GABA B receptor activation. In the presence of TTX to block action potential-mediated neurotransmitter release, stimulation with exogenously applied glutamate triggered a robust postsynaptic Ca 2ϩ rise that was dramatically depressed (Ͼ70% in cortical neurons, Ͼ40% in hypothalamic neurons) by baclofen. Together these data suggest both a pre-and postsynaptic component for the modulatory actions of the GABA B receptor. These results indicate a potentially important role for the GABA B receptor as a modulator of the excitatory actions of glutamate in developing neurons.
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I N T R O D U C T I O N
In neurons, tight regulation of intracellular Ca 2ϩ is essential for normal cellular functions. Even slight changes in neuronal Ca 2ϩ levels can influence a myriad of biochemical pathways involved in enzyme activation, gene expression, transmitter release, and cytoskeletal remodeling (Clapham 1995; De Camilli and Takei 1996; . In addition, during early development changes to intracellular Ca 2ϩ can alter growth cone motility and the rate of neurite outgrowth (Mattson and Kater 1987) as well as synapse formation (Nelson et al. 1990 ), neural migration (Komuro and Rakic 1996) , and neural phenotype (Marty et al. 1996) . One principal mechanism by which neuronal Ca 2ϩ levels are regulated is through the interplay of excitatory and inhibitory neurotransmitter systems. In the CNS, the widespread amino acid neurotransmitters glutamate and GABA play a primary role in regulating synaptic neurotransmission and thereby cytosolic Ca 2ϩ levels. The ability of glutamate to both elicit fast excitatory neurotransmission and increase cytosolic Ca 2ϩ results from the activation of the ionotropic class of glutamate receptors (Nakanishi 1992) and subsequent activation of voltage-gated Ca 2ϩ channels. In addition to the normal regulation of Ca 2ϩ , excitotoxicity can result from an extreme elevation in internal Ca 2ϩ caused by excessive levels of glutamate or an increase in glutamate sensitivity (Choi 1992) .
In the mature nervous system, GABA acts as the primary fast inhibitory neurotransmitter. The hyperpolarizing actions of GABA result from the activation of the ligand-gated GABA A receptor. For example, glutamate-evoked membrane depolarization and subsequent Ca 2ϩ influx are decreased by GABA A receptor activation in mature neurons. In contrast to the mature nervous system, during early development GABA A receptors act to increase cytosolic Ca 2ϩ levels. By activating Cl Ϫ -dependent inward current at GABA A receptors, GABA can depolarize the membrane potential and increase the frequency of action potentials (Chen et al. 1996; Owens et al. 1996) , thus resulting in membrane depolarization, activation of voltagedependent Ca 2ϩ channels, and intracellular Ca 2ϩ increases (Obrietan and van den Pol 1995b; Reichling et al. 1994) . These results raise the question of whether there is a Ca 2ϩ inhibitory role for GABA independent of the GABA A receptor during development.
Another mechanism by which GABA may negatively affect cytosolic Ca 2ϩ levels is through the activation of the GABA B subclass of receptors. GABA B receptors operate through G proteins (Bowery 1993; Misgeld et al. 1995) and are expressed both presynaptically (Dutar and Nicoll 1988a; Howe et al. 1987; Yoon and Rothman 1991) and postsynaptically (Solis and Nicoll 1992) . At their presynaptic location, GABA B receptors have been shown to decrease neurotransmitter release by increasing K ϩ conductance or by decreasing Ca 2ϩ conduc-tance (Bowery 1993; Misgeld et al. 1995) . Presynaptically, GABA B receptors may also play a role as autoreceptors, negatively regulating the synaptic release of GABA (Anderson and Mitchell 1985; Pittaluga et al. 1987) . Activation of postsynaptic GABA B receptors has been shown to induce K ϩ currents, leading to membrane hyperpolarization (Alger and Nicoll 1982; Dutar and Nicoll 1988b) and to inhibit voltage-dependent Ca 2ϩ channels (Lambert and Wilson 1996; Misgeld et al. 1995) .
Although receptor autoradiography binding studies revealed that in some brain regions GABA B receptor expression is greater during development than in the adult (Turgeon and Albin 1994) , the physiological effects of GABA B receptors on developmentally immature neurons were not thoroughly characterized. Given that GABA and glutamate are released from axon terminals within 4 days of final mitosis and that both transmitters have the capacity to increase Ca 2ϩ and act in synergy to increase action potentials (Gao et al. 1998) , it is unclear what mechanisms are involved with attenuating runaway excitation generated by the depolarizing actions of GABA and glutamate during neural development. We tested the hypothesis that GABA acting at the GABA B receptor would decrease glutamate-dependent excitability, as detected by inhibition of glutamate-mediated Ca 2ϩ elevations. Previously, we have shown that GABA B receptor activation regulates Ca 2ϩ transients mediated by GABA A receptors during early development .
The results presented here reveal a potent inhibitory action of GABA B receptors on glutamate-mediated Ca 2ϩ transients. These results strongly suggest that GABA B receptors may play a substantial role in regulating glutamatergic neurotransmission in developing cortical and hypothalamic neurons.
M E T H O D S

Tissue culture
The region of the mediobasal hypothalamus from the caudal preoptic area to the mammillary bodies was excised from SpragueDawley rats on embryonic day 18 (E18). The area of the fornix and mammillothalalmic tract was used as the general lateral boundary. The tissue was washed by resuspending it three times in culture medium (DMEM, Gibco) and then incubating it in a mild proteolytic solution (10 units/ml papain, 0.2 mg/ml L-cysteine in Earl's balanced salt solution). After 30 min, the digestion was stopped by pelleting the tissue and removing the protease solution. Tissue was then suspended in standard tissue culture medium (glutamate-and glutamine-free DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin/streptomycin and 6 gm/l glucose). Next a fire-polished pasteur pipette was used to triturate the tissue into a single cell suspension. The tissue was pelleted and washed three additional times. Cells were then plated (ϳ100,000 cells/cm 2 ) onto 22 mm 2 glass coverslips coated with high molecular weight polylysine (MW 540 kD, Collaborative Research). To ensure high local neuronal density, cells were plated within a glass cylinder (7 mm diam) placed on the coverslip. The cylinder was removed 45 min after plating. Hypothalamic cells were cultured in a Napco incubator at 5% CO 2 and 37°C and maintained in standard tissue culture medium. Two days after plating, cytosine arabinofuranoside (6 M) was added to the media to inhibit cell proliferation. Media was changed twice a week. The identical culturing protocol as described for the hypothalamus was used to culture neurons from the cortex. To generate hyperexcitable hypothalamic neurons (Obrietan and van den Pol, 1995a) used in Fig.  6 , 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (10 M) and D,L-2-amino 5 phosphono valerate (D,L-AP5) (100 M) were added to the tissue culture medium 3 days after plating and maintained in the media throughout time in culture.
Calcium digital imaging
Cells were incubated in standard HEPES perfusion solution (137 mM NaCl, 25 mM glucose, 10 mM HEPES, 5 mM KCl, 1 mM MgCl 2 , 3 mM CaCl 2 , pH 7.4) containing 5 M fura-2 acetoxymethyl ester (Molecular Probes) for 20 min at 37°C. To inhibit synaptic activity in chronically blocked cultures, ionotropic glutamate receptor inhibitors AP5 (100 M) and CNQX (10 M) or TTX (1 M) were added to the incubation solution. The cells were washed two times after loading and then allowed to recover for 30 min. The coverslip was then loaded into an eight-port, 180 l, microscope perfusion chamber (Forscher et al. 1987 ) and perfused at a constant rate. Solutions moved as a straight wave across the perfusion chamber, with total exchange of solution occurring in ϳ5 s. Neurons were identified by their phase-bright appearance and by their responsiveness to the application of N-methyl-D-aspartate (NMDA). Ca 2ϩ recordings were made from the cell soma. All experiments were performed at room temperature. To enhance NMDA receptor activity during endogenous activity experiments, 2 M glycine was added, and Mg 2ϩ was removed from the standard HEPES perfusion solution. Image collection was performed with a ϫ40 Olympus objective with high 340/380 nm transmittance on a Nikon Diaphot 300 inverted microscope. Fluorescent light was passed back through the objective, through a 420 nm cutoff filter, and directed at a Hamamatsu 2400 silicon-intensified target video camera. Recordings at 340 and 380 nm excitation were controlled by a 486 PC with Fluor software (Universal Imaging). Switching between the two excitation filters was performed with a Sutter filter wheel connected to a Lambda 10 microprocessor; 90% neutral density filter attenuation of light from a 150-W xenon lamp allowed for recordings of Ͼ90 min without detectable phototoxicity. Sixteen video frames (500 ms) were collected every 5 s and averaged after background subtraction. The equation [Ca 2ϩ ]i ϭ K d (R Ϫ R min )/(R max Ϫ R) was employed to determine free Ca 2ϩ concentrations from fura-2 ratiometric fluorescent Ca 2ϩ values. R is defined as the ratio of the two fluorescence intensities, R min is the ratio in the absence of Ca 2ϩ , and R max is the ratio in a saturating concentration of Ca 2ϩ . The K d for binding of Ca 2ϩ to fura-2 was taken to be 224 nM (Grynkiewicz et al. 1985) . Data analysis was performed with Igor Pro software (WaveMetrics, Lake Oswego, OR).
For assays that evoked a Ca 2ϩ response by exogenous administration of glutamate, the peak Ca 2ϩ rise (either in the presence or absence of baclofen) for individual neurons was determined by subtracting the mean basal Ca 2ϩ level for a 15 s period just before stimulation from the peak glutamate-evoked Ca 2ϩ rise. The mean Ca 2ϩ rise triggered by synaptic glutamate release after withdrawal of receptor antagonists (or TTX) was determined for a 15-s period immediately preceding the administration of GABA B agonists and/or antagonists. This value was compared with the mean Ca 2ϩ rise over a 15 s period 30 s after addition of the GABA B receptor antagonist or 90 s after addition of GABA B agonists. Data for both experimental protocols are reported as a mean (pooled) Ca 2ϩ rise of all responsive neurons Ϯ SE. A responsive neuron was defined as a neuron that showed a Ն20 nM Ca 2ϩ rise to either exogenous glutamate application or synaptic glutamate release.
Reagents
Cytosine arabinofuranoside, glutamate, and poly-D-lysine were acquired from Sigma; AP5, CNQX, bicuculline, R(ϩ)-baclofen, 2-hydroxy-saclofen, NMDA, and TTX from Research Biochemicals International; papain from Worthington Biochem; DMEM from Gibco; and fura-2 acetoxymethyl ester from Molecular Probes. CGP 35348 was a generous gift of Ciba-Geigy AG (Basel).
R E S U L T S
The removal of the ionotropic glutamate receptor antagonists AP5 (100 M) and CNQX (10 M) from the perfusion solution initiated an increase in basal Ca 2ϩ levels and a series of complex Ca 2ϩ transients in both hypothalamic and cortical neurons cultured for 7 days from E18 rats (Fig. 1, A and B) . Previous work has shown that by 7 days in vitro neurons cultured under these conditions form synaptic connections and secrete neurotransmitter . That the Ca 2ϩ transients shown in Fig. 1A were initiated by the withdrawal of ionotropic glutamate receptor antagonists indicates the synaptic release of glutamate. The mean Ca 2ϩ rise elicited by AP5 and CNQX withdrawal was 123 Ϯ 8 nM in hypothalamic and 156 Ϯ 11 nM in cortical neurons. GABA B receptor activation mediated by the administration of the specific agonist R(ϩ)-baclofen (baclofen: 10 M) depressed the mean Ca 2ϩ rise to 3 Ϯ 5 nM, representing a decrease in the glutamate-mediated rise of ϳ95% in hypothalamic neurons (n ϭ 38; Fig. 1A ). In cortical neurons baclofen (10 M) decreased the Ca 2ϩ rise to 17 Ϯ 5 nM (n ϭ 43; Fig. 1B ). Large Ca 2ϩ transients were again found immediately after baclofen washout. Ca 2ϩ levels in 82 of 119 synaptically active hypothalamic neurons were depressed Ͼ80% by baclofen. The effects of baclofen were dose dependent in hypothalamic neurons ( Fig.  1E ) as well as in cortical neurons (data not shown). The inhibitory effects of baclofen were observed from the earliest [6 days in vitro (DIV)] to the latest (32 DIV) time point tested.
In some hypothalamic neurons baclofen depressed cytosolic Ca 2ϩ to a concentration lower than the concentration in the presence of AP5 and CNQX. An example of this is shown in Fig. 1A (bottom neuron: arrow). To asses whether this effect resulted from a capacity of the GABA B receptor to alter Ca 2ϩ homeostasis independent of glutamate transmission, baclofen was administered in the presence of TTX (1 M; Fig. 1C ). TTX blocks action potential-mediated neurotransmitter release. Under this condition, baclofen administration resulted in a small but significant (P Ͻ 0.0001, two tailed t-test) 12% decrease in basal Ca 2ϩ levels in hypothalamic neurons (Fig.  1F , n ϭ 189). Similar results were observed when baclofen was administered in the presence of AP5 and CNQX (data not shown). No significant alteration in basal Ca 2ϩ levels was observed in cortical neurons (Fig. 1, D and F ; n ϭ 98).
Early in hypothalamic development GABA acts as an excitatory neurotransmitter, leading to membrane depolarization (Chen et al. 1996) and triggering cytosolic Ca 2ϩ rises (Obrietan and van den Pol 1995b) . Given this, the data presented in Fig. 1 may have resulted from a modulation of excitatory GABAergic stimulation that in turn would affect glutamatergic transmission. To address this possibility, 6 DIV neurons released from glutamate receptor blockade were exposed to the GABA A receptor antagonist bicuculline (20 M; Fig. 2 ). Under these conditions, administration of baclofen (10 M) resulted in a dramatic decrease in glutamate-dependent Ca 2ϩ transients (Fig. 2) . In the presence of bicuculline, the mean Ca 2ϩ rise after AP5/CNQX withdrawal was 101 Ϯ 6 nM. Baclofen treatment depressed the mean Ca 2ϩ rise to 21 Ϯ 6 nM, representing an ϳ80% decrease in the glutamate-mediated Ca 2ϩ rise (n ϭ 44). These results reveal that in the absence of excitatory GABA A receptor activity the GABA B receptor can modulate glutamate neurotransmission.
Given the potent short-term Ca 2ϩ modulatory effects of GABA B receptor activation, we tested whether this effect would persist for an extended time period. Figure 3A shows that spontaneous glutamate-mediated Ca 2ϩ transients could be totally inhibited for Ͼ10 min by baclofen (100 M). The modulatory effects of baclofen did not significantly desensitize in any of the neurons assayed (n ϭ 47). Ca 2ϩ transients resumed after baclofen washout. Administration of AP5 (100 M) and CNQX (10 M) at the end of the experiment returned Ca 2ϩ to basal levels that were slightly higher than the Ca 2ϩ level observed in the presence of baclofen. One possible mechanism by which GABA B receptors could affect glutamate-mediated Ca 2ϩ transients is through the activation of Gi-coupled proteins. To test this cellular signaling mechanism, hypothalamic and cortical neurons were pretreated with the Gi inhibitor pertussis toxin (200 ng/ml, 16 h). Pertussis toxin pretreatment largely blocked the inhibitory effects of baclofen (10 M) in both hypothalamic (Fig. 3B ) and cortical neurons (Fig. 3C) . Figure 3D shows the mean Ca 2ϩ rise in the absence (open bars) and in the presence (solid bars) of baclofen in pertussis toxin-treated neurons. Compared with the inhibitory effects of baclofen (10 M) described in Fig. 1 , pertussis toxin pretreated reduced the efficacy of baclofen by more than eightfold for hypothalamic and by more than twofold for cortical neurons. These data suggest that a principal mechanism by which GABA B receptor activation alters glutamate responsiveness is via activation of Gi.
GABA B receptors may affect glutamate-dependent signaling by altering transmitter release and/or by altering the postsynaptic responsiveness to glutamate. To address the latter possibility, postsynaptic Ca 2ϩ responses evoked by exogenous glutamate administration were compared with Ca 2ϩ responses evoked by glutamate in the presence of baclofen. All perfusion solutions contained TTX (1 M) to block presynaptic transmitter release. Administration of glutamate (Fig. 4, A rise in the presence of baclofen), we found that of the 317 neurons assayed baclofen reduced the glutamate-dependent Ca 2ϩ increase by Ͼ20% in 90% of hypothalamic neurons and by Ͼ20% in 98% of cortical neurons. In some hypothalamic (Fig. 4A, top neuron) and cortical (Fig. 4B) subtract the purely postsynaptic site of action (exogenous application) from the pre-and postsynaptic site of action (revealed by synaptic glutamate release protocol). To control for a varied Ca 2ϩ responsiveness under these two protocols, only neurons exhibiting a rise of 150 -300 nM were used. For hypothalamic neurons, the Ca 2ϩ rise to synaptically released glutamate was 207 Ϯ 21 nM; in the presence of baclofen the Ca 2ϩ rise was 20 Ϯ 11 nM n ϭ 31. For exogenously evoked glutamate response, the Ca 2ϩ rise was 239 Ϯ 10 nM. In the presence of baclofen the Ca 2ϩ rise was 83 Ϯ 15 nM (n ϭ 27). The significantly (P Ͻ 0.005, two-tailed t-test) greater level of baclofen depression of synaptic glutamate-dependent Ca 2ϩ rises compared with bath-applied glutamate suggests a modulatory role for presynaptic GABA B receptors. In cortical neurons, the Ca 2ϩ rise to synaptically release glutamate was 210 Ϯ 10 nM; in the presence of baclofen the Ca 2ϩ rise was 25 Ϯ 4 nM (n ϭ 42). The exogenously evoked Ca 2ϩ rise was 240 Ϯ 7 nM. In the presence of baclofen the Ca 2ϩ rise was 57 Ϯ 10 (n ϭ 42). For cortical neurons, the difference in the modulatory actions of baclofen between these two protocols was statistically significant (P Ͻ 0.005, two-tailed t-test). Consistent with electrophysiological recordings (see DISCUSSION) , these results suggest that functional GABA B receptors are expressed presynaptically and augment the postsynaptic actions of GABA B receptors.
To ensure that the effects of baclofen were specific to the GABA B receptor, 2-hydroxy-saclofen (200 M), a GABA B receptor antagonist (Curtis et al. 1988; Harrison et al. 1990; Lambert et al. 1989) , was co-administered with baclofen (10 M). Figure 5 , A and B, shows that the inhibitory effects of baclofen were attenuated by 2-hydroxy-saclofen. The mean Ca 2ϩ rise triggered by AP5 and CNQX withdrawal from hypothalamic neurons was 127 Ϯ 9 nM. Baclofen reduced this Ca 2ϩ rise to 5 Ϯ 6 nM. In combination with 2-hydroxy- saclofen the mean Ca 2ϩ decrease mediated by baclofen was 76 Ϯ 10 nM (n ϭ 83).
Next we assessed whether the synaptic release of GABA could depress glutamatergic Ca 2ϩ rises via activation of the GABA B receptor. When administered alone, 2-hydroxysaclofen dramatically potentiated the glutamate-regulated Ca 2ϩ level (Fig. 5B ). This effect is also shown for repeated 2-hydroxy-saclofen (200 M) administrations in Fig. 5C . In this neuron, the Ca 2ϩ transients mediated by glutamatergic neurotransmission are potentiated by approximately threefold by blockade of GABA B receptor activation. On average, 2-hydroxy-saclofen increased glutamate-mediated Ca 2ϩ transients by 54 Ϯ 10 nM (n ϭ 87). Similar results were observed with another GABA B receptor antagonist, CGP 35348 (400 M; Fig. 5E ). A graphic representation of these results is shown in Fig. 5F . Figure 5D shows that 2-hydroxy-saclofen (200 M) did not significantly alter basal Ca 2ϩ levels when spontaneous glutamatergic neurotransmission was blocked with TTX (1 M; n ϭ 79). Administration of NMDA (100 M) at the end of the experiment was used to show that the neurons were healthy and responsive to glutamate receptor stimulation. These results reveal that synaptically released GABA acts at GABA B receptors to depress Ca 2ϩ transients triggered by synaptic glutamate release.
For normal cellular functions, intracellular Ca 2ϩ must be maintained within a relatively narrow concentration range. If cytosolic Ca 2ϩ levels exceed a critical threshold, cell death will result. In the CNS, excessive glutamatergic stimulation can lead to cell death as a result of triggering massive Ca 2ϩ influx (Choi 1992 ). Previously, we have shown that hypothalamic neurons raised in the constant presence of AP5 and CNQX become hyperexcitable, thus leading to toxic levels of intracellular Ca 2ϩ after glutamate receptor antagonist withdrawal (Obrietan and van den Pol 1995a) . To asses the modulatory role of GABA B receptor activation under this condition of hyperexcitability, hypothalamic neurons were cultured for 29 days in the constant presence of AP5 and CNQX. Withdrawal of short-term TTX (1 M) pretreatment elicited a Ca 2ϩ rise (Fig. 6A) . Enhancing NMDA receptor responsiveness by the withdrawal of Mg 2ϩ and addition of glycine (2 M) to the perfusion solution increased the Ca 2ϩ activity further. Additionally, blockade of the inhibitory influence of tonic GABA A receptor activation by administration of the antagonist bicuculline (20 M) triggered a massive potentiation of glutamatergic Ca 2ϩ rises. Under this condition Ca 2ϩ levels exceeded 1,500 nM in the representative neuron shown in Fig. 6 . We have previously shown that this level of cytosolic Ca 2ϩ is potentially toxic to hypothalamic neurons over an extended period (Obrietan and van den Pol 1995a) . Under this condition, the administration of baclofen (100 M) resulted in a large decrease in the glutamate-mediated Ca 2ϩ rise. After withdrawal of baclofen, Ca 2ϩ levels immediately rose to prebaclofen levels. Of the neurons showing Ͼ500 nM Ca 2ϩ rise after bicuculline administration, 35% had a Ͼ50% reduction in Ca 2ϩ levels, whereas 70% of neurons exhibited Ͼ30% inhibition after baclofen administration (n ϭ 58). Single-cell response profiles are displayed in a histogram format (Fig. 6B) . These results reveal that even under extreme, potentially toxic levels of glutamate neurotransmission GABA B receptors have the potent capacity to reduce cytotoxic Ca 2ϩ levels.
D I S C U S S I O N
The results presented here are the first to characterize a potent Ca 2ϩ regulatory role for the GABA B receptor in hypothalamic and in cortical glutamatergic neurons during development. Stimulation of GABA B receptors depressed Ca 2ϩ transients mediated by the synaptic release of glutamate and by postsynaptic stimulation of glutamate receptors. Additionally, the finding that GABA B receptors are tonically activated and thus lead to a decrease in Ca 2ϩ transients mediated by synaptic glutamate release suggests an important regulatory role for the GABA B receptor during development.
We observed potent, dose-dependent GABA B receptormediated depression of Ca 2ϩ transients resulting from the synaptic release of glutamate in hypothalamic neurons. This Ca 2ϩ rise was the result of glutamate release because administration of the glutamate receptor antagonists AP5 and CNQX to the perfusion solution blocked the Ca 2ϩ transients. Relative to other glutamate neuromodulators that we characterized (neuropeptide Y, adenosine, and dopamine), we found that the GABA B receptor was very effective at depressing glutamatemediated Ca 2ϩ transients van den Pol et al. 1996a,b) . For example, adenosine receptor activation could, at saturating agonist concentration, only decrease a maximum of 78% of the Ca 2ϩ rise resulting from synaptic glutamate release, whereas the Ca 2ϩ rise resulting from synaptic glutamate release could be completely blocked by baclofen. Possible reasons for this may include a greater number of GABA B receptors per neuron or tighter coupling to second-messenger signaling pathways
The inhibitory effects of baclofen persisted for the duration of its presence. We did not observe recovery of glutamatergic Ca 2ϩ transients suggestive of GABA B receptor desensitization, even during extended treatments (Ͼ10 min). However, immediately after withdrawal of baclofen, glutamatergic transients were re-initiated. This potent inhibition of glutamatergic Ca 2ϩ transients has not been previously observed. However, electrophysiological studies have shown that decreased membrane conductance mediated by baclofen was not attenuated during extended treatments lasting for ϳ10 min (Bon and Galvan 1996; Fujikawa et al. 1997) .
Stimulating GABA B receptors with baclofen resulted in a potent depression of Ca 2ϩ rises evoked by exogenous administration of glutamate to cortical or hypothalamic neurons. Because the presynaptic release of glutamate was blocked with TTX, the observed inhibitory effect of GABA B receptor activation in those experiments reflected a postsynaptic site of action. Postsynaptic GABA B receptors were previously observed in a number of brain regions, including the hippocampus (Yoon and Rothman 1991) and spinal cord (Beattie et al. 1989) , but appear to be absent in other brain regions such as the striatum (Nisenbaum et al. 1993) . Our observed postsynaptic effect of baclofen in cortical neurons is in agreement with work showing postsynaptic expression of GABA B receptors in the cortex (Karlsson and Olpe 1989) . Besides our previous work and the data presented here, little has been done to characterize postsynaptic actions of the GABA B receptor in the hypothalamus. The postsynaptic physiological effect most often resulting from GABA B receptor stimulation is an increase in K ϩ conductance (Loose et al. 1991; Misgeld et al. 1995) , although this may be absent from some hypothalamic regions, such as the suprachiasmatic nucleus . Membrane hyperpolarization resulting from increased K ϩ conductance would decrease neural excitability.
The depression of postsynaptic glutamate responses by baclofen could be explained by the ability of the GABA B receptor to modulate second-messenger systems. For example, the GABA B receptor has been shown to couple to decreased cAMP production (Desrues et al. 1995; Hashimoto and Kuriyama 1997) . We observed that GABA B receptor-mediated inhibition was significantly decreased by pretreatment with pertussis toxin, suggesting that GABA B receptors in cortical and hypothalamic neurons are coupled to heteromeric Gi proteins. Decreased adenylyl cyclase activity resulting from Gi release from the ␤-and ␥-regulatory subunits would negatively regulate cAMP-dependent protein kinase activity and thereby potentially alter the phosphorylation state of glutamate receptors. Along these lines cAMP-dependent protein kinases were found to modulate kainate receptors (Keller et al. 1992; Raymond et al. 1993) and NMDA receptor conductance (Cerne et al. 1993 (Lambert and Wilson 1996) . The varied level of GABA B -mediated inhibition of glutamateevoked Ca 2ϩ rises observed in hypothalamic cultures may result from the varied expression of Ca 2ϩ channel subtypes found in hypothalamic neurons (Zeilhofer et al. 1991) or to differences in glutamate receptor expression (van den Pol et al., 1994) or phosphorylation state of the glutamate receptors.
Given that the level of baclofen-mediated depression of postsynaptic glutamate-evoked Ca 2ϩ rises (in the presence of TTX) was not as great as the level of depression resulting from synaptically released glutamate, our results suggests the functional expression of presynaptic GABA B receptors. Along these lines, several studies have shown that GABA B receptors are expressed in presynaptic nerve terminals where they act to reduce transmitter release from hypothalamic and nonhypothalamic (Fukuda et al. 1993; Howe et al. 1987; Isaacson et al. 1993) neurons. There may be several presynaptic mechanisms initiated by GABA B receptors that result in decreased transmitter release. For example, GABA B receptor activation has been shown to reduce transmitter release by hyperpolarizing the membrane potential via elevated K ϩ currents (Gerber and Gahwiler 1994) and by inhibiting several different types of voltage-activated Ca 2ϩ channels (Doze et al. 1995; Matsushima et al. 1993; Mintz and Bean 1993; Shibuya and Douglas 1993; Wall and Dale 1994) .
Changes in cytosolic Ca 2ϩ levels affect a variety of processes essential for nervous system development. The ability of glutamate to increase cytosolic Ca 2ϩ levels during development indicates that it plays an important role defining CNS cytoarchitechture. Given the widespread expression of glutamate-secreting cells in the CNS, one would expect that glutamate-mediated Ca 2ϩ rises should be negatively regulated by other transmitter systems. One candidate inhibitory transmitter is GABA. This possibility is supported by the high percentage of GABAergic cells in the CNS, the high levels of GABA immunoreactivity found in axonal growth cones (van den Pol 1997) , and the observation that GABA is released from axon terminals within 3 or 4 days of the final mitosis (Obrietan and van den Pol 1995b; van den Pol et al. 1995 van den Pol et al. , 1998 . Given that during early development GABA, acting at the GABA A receptor, is primarily an excitatory neurotransmitter (Chen et al. 1996; Owens et al. 1996) , we turned our focus to the GABA B receptor. The work presented here reveals a prominent inhibitory action on the excitatory effects of glutamate. Coupled with our previous report showing that GABA B receptors also reduce the excitatory actions of GABA acting at the GABA A receptor these results are consistent with the idea that the GABA B receptor may play an important modulatory role in reducing transmitter-regulated Ca 2ϩ transients in developing neurons.
Under some conditions, GABA-and glutamate-containing axons may compete for postsynaptic sites during early synaptogenesis. On the basis of Hebbian models of synaptic strengthening, the ability of GABA to reduce glutamate actions in developing neurons at both pre-and postsynaptic sites hypothetically may provide a competitive advantage for the depolarizing actions of GABA at the GABA A receptor.
